newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and